<p>This volume contains a collection of relevant information for drug discovery in cell cycle research. Protocols to develop screening assays or to identify novel CDK inhibitors are discussed in the first part of the book. The second part of the book describes elaborate procedures to evaluate activi
Cyclin Dependent Kinase (CDK) Inhibitors
β Scribed by M. D. Mendenhall (auth.), Professor Peter K. Vogt Ph.D., Professor Steven I. Reed Ph.D. (eds.)
- Publisher
- Springer-Verlag Berlin Heidelberg
- Year
- 1998
- Tongue
- English
- Leaves
- 175
- Series
- Current Topics in Microbiology and Immunology 227
- Edition
- 1
- Category
- Library
No coin nor oath required. For personal study only.
β¦ Synopsis
More than 10 years ago, the discovery of cyclin-dependent kiΒ nases (Cdks) ushered in a new era in the understanding of cell proliferation and its control. Not only were both of the known cell cycle transitions, from G 1 to S phase and G2 to M phase, found to be dependent on these protein kinases, but the regΒ ulatory assumption intrinsic to cyclin-dependent kinases, a stable inactive catalytic subunit (the Cdk) and an unstable requisite positive regulatory activating subunit (the cyclin), led to a simple model for cell cycle control. Modulation of cyclin accumulation, and thereby Cdk activation, was proposed to be the overarching principle governing the passage through cell cycle phases. AnΒ other reality to emerge from the discovery of Cdks was the exΒ ceptional degree of evolutionary conservation maintained in the machinery and organization of proliferation control. Not only were Cdks shown to be structurally conserved between yeast and man, but mammalian Cdks could substitute functionally for the endogenous enzymes in a yeast cell. The problem of cell cycle control was thought to have been virtually solved. The ensuing years have provided a much more complex view of cell cycle control and the role and regulation of Cdks. The uncritical enthusiasm with which many of the ideas were emΒ braced has required tempering. For example, although Cdks appear to be highly conserved phylogenetically, cyclins are much less so.
β¦ Table of Contents
Front Matter....Pages I-XI
Cyclin-Dependent Kinase Inhibitors of Saccharomyces cerevisiae and Schizosaccharomyces pombe ....Pages 1-24
Inhibitors of the Cip/Kip Family....Pages 25-41
The INK4 Family of CDK Inhibitors....Pages 43-55
Role of Cyclin-Dependent Kinases and Their Inhibitors in Cellular Differentiation and Development....Pages 57-103
Roles of Cyclin-Dependent Kinase Inhibitors: Lessons from Knockout Mice....Pages 105-120
p21/p53, Cellular Growth Control and Genomic Integrity....Pages 121-137
Cyclin-Dependent Kinase Inhibitors and Human Cancer....Pages 139-148
Small-Molecule Inhibitors of Cyclin-Dependent Kinases: Molecular Tools and Potential Therapeutics....Pages 149-165
Back Matter....Pages 167-172
β¦ Subjects
Immunology; Cell Biology; Cancer Research; Biochemistry, general
π SIMILAR VOLUMES
<p><p>This volume contains a collection of relevant information for drug discovery in cell cycle research. Protocols to develop screening assays or to identify novel CDK inhibitors are discussed in the first part of the book. The second part of the book describes elaborate procedures to evaluate act
<p><P><STRONG><EM>Cyclin Dependent Kinase 5</EM></STRONG> provides a comprehensive and up-to-date collection of reviews on the discovery, signaling mechanisms and functions of Cdk5, as well as the potential implication of Cdk5 in the treatment of neurodegenerative diseases. Since the identification
One of the few books to cover all aspects of cyclin-dependent kinases (CDKs), Inhibitors of Cyclin-dependent Kinases as Anti-tumor Agents provides an overview of CDKs as molecular and functional entities, their involvement in different disease processes, and their potential for pharmacological modul
<P><EM><STRONG>Cyclin Dependent Kinase 5 </EM> provides a comprehensive and up-to-date collection of reviews on the discovery, signaling mechanisms and functions of Cdk5, as well as the potential implication of Cdk5 in the treatment of neurodegenerative diseases. Since the identification of this uni